A Phase 1 interventional study of CSB-001 Ophthalmic Solution 0.1% in Limbal Stem Cell Deficiency, sponsored by Claris Biotherapeutics, Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Claris Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).
38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.
This study's planned enrollment of 75 is above the median of 20 across 23 interventional studies indexed under Limbal Stem Cell Deficiency.
Browse Limbal Stem Cell Deficiency studies →Claris Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion/exclusion criteria apply.
Period I: Subjects will be observed (non-interventional) for 20 weeks. Period II: Subjects will be dosed one drop CSB-001 four times daily for two 8-week dosing periods in the study eye(s) separated by \>30 days and \<40 days (dosing holiday) followed by observation (non-interventional) to Week 48. Period III: Subjects may elect to participate in the Observation Extension Phase (non-interventional) for an additional 36 months to Week 144.
Biological: CSB-001 Ophthalmic Solution 0.1%
Period I: Subjects will be dosed one drop CSB-001 four times daily for two 8-week dosing periods in the study eye(s) separated by \>30 days and \<40 days (dosing holiday) followed by observation (non-interventional) to Week 20. Period II: Subject will be observed (non-interventional) for 28 weeks to Week 48. Period III: Subjects may elect to participate in the Observation Extension Phase (non-interventional) for an additional 36 months to Week 144.
Biological: CSB-001 Ophthalmic Solution 0.1%
CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
Safety as Assessed by Adverse Event Reporting
Incidence of ocular and systemic adverse events
Time frame: Day 0 through Week 144
Safety as Assessed by Slit-lamp Biomicroscopy
Change from baseline in slit-lamp parameters
Time frame: Day 0 through Week 144
Safety as Assessed by Best-corrected Distance LogMAR Visual Acuity
Change from baseline using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart
Time frame: Day 0 through Week 144
Efficacy as Assessed by Change in Stage of LSCD
Change from baseline in LSCD signs based on imaging (white light, blue light with fluorescein and Wratten filter, and AS-OCT)
Time frame: Day 0 through Week 144
Efficacy as Assessed by Change in Best-corrected Distance LogMAR Visual Acuity
Visual acuity measured using the EDTRS visual acuity chart
Time frame: Day 0 through Week 144
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2027, 43 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CSB-001
Claris Biotherapeutics, Inc.